Sugi Predict

Sugi Predict / Compounds / SCHEMBL3763628

SCHEMBL3763628

SCHEMBL3763628

CCOC(=O)C#Cc1cnc(NC(=O)OC(C)(C)C)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 4/20 0.39
▸ CDK2 P24941 4/20 0.39
▸ CDK1 P06493 3/20 0.39
▸ CDK4 P11802 3/20 0.39
▸ CCNE2 O96020 3/20 0.39
▸ CCNB2 O95067 2/20 0.39
▸ CCNB1 P14635 2/20 0.39
▸ CCND1 P24385 2/20 0.39
▸ CCNB3 Q8WWL7 2/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ LCK P06239 4/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ FPR3 P25089 1/20 0.35
▸ FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013536 0.79 CA1 (0.41) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL948557 0.79 CDC7 (0.47) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL15172488 0.78 CA1 (0.40) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL31282374 0.77 FFAR2 (0.52) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL3018930 0.77 CA1 (0.44) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL29276894 0.76 CA1 (0.41) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL21222206 0.75 ALDH1A1 (0.62) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL12241503 0.74 RAB9A (0.52) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL18023319 0.74 RARB (0.43) CCNE1CDK2CDK1CDK4CCNE2
SCHEMBL3768855 0.73 SMN1; SMN2 (0.51) ALDH1A1MAPTSMN1; SMN2TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 — — US disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 — — US disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 — — US disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 — — US disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 — — US disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA CCNE1 3436/4885CDK2 684/4885CDK1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.